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Introduction: Low-molecular-weight heparin (LMWH) is frequently recommended for the treatment of pregnancy
associated venous thromboembolism (PAVTE). Given that prior reports have suggested a wide variation in dosing of
LMWH in pregnancy and the use of anti-Xa monitoring in pregnancy, the principal aim of this survey was to assess
current practices for the management of PAVTE.
Methods: An electronic survey was conducted. The target sample was members of the North American Society of
Obstetric Medicine and Thrombosis Interest Group of Canada.
Results: The final sample consisted of 27/69 hematologists (39.1%), 30/69 internists (43.5%), 8/69 obstetricians
(11.6%), and 4/69 from other specialties (5.7%). For the acute treatment of patients pregnant patients with deep
vein thrombosis 42/69 (60.8%) preferred LMWH given twice a day 42/69 (60.8%), whereas 25/69 (36.2%) preferred
once daily. These results were similar for patients with pulmonary embolism (PE). For long-term treatment more
than 70% of the respondents favoured treatment with full doses of LMWH given once a day or twice a day and
16/69 (23.2%) intermediate doses for patients diagnosed with DVT. These results were similar for patients with
PE. Fourteen physicians out of 69 (20.3%) did not measure anti-Xa monitoring during acute treatment period
and 24/69 (34.8%) never used anti-Xa levels during the long term treatment period. Management during the
peri-partum period varied widely according to the time of the diagnosis of PAVTE.
Discussion: In conclusion, our survey shows wide variation in practice regarding LMWH dosing and anti-Xa
monitoring in pregnancy associated VTE and calls for trials comparing different long term strategies using
LMWH in patients with PAVTE.
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Low-molecular-weight heparin (LMWH) is frequently
recommended for the treatment of pregnancy associated
venous thromboembolism (PAVTE) [1]. Normal physio-
logic changes occurring during pregnancy affect the
pharmacokinetics of LMWH that result in increasing
dose requirements in pregnancy (due to a greater vol-
ume of distribution and increased renal clearance) [2].
Consequently in patients with PAVTE a more aggressive
approach using continuous full doses of LMWH, given
twice daily and tailored to anti-Xa levels is commonly* Correspondence: egandara@ohri.ca
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reproduction in any medium, provided the orused [3,4] during the acute treatment period (first 1–4
weeks) and long-term treatment (>1-4 weeks) without
supporting evidence from high quality studies or current
clinical guidelines [1]. The principal aim of this survey
the principal aim of this survey was to assess current
practices for the management of PAVTE.Methods
An electronic self-response survey, using Survey Monkey
software was conducted. The target sample was experts
and clinicians with experience in the management of
VTE associated with pregnancy. An information sheet/
electronic statement indicating that participation was
voluntary and ensuring confidentiality was provided with
each survey. Two groups agreed to collaborate with this
project: 1-The Thrombosis Interest Group of Canadal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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medicine (ISOM). The protocol was approved by the
Ottawa Hospital Ethics and Research board to initiating
the survey. The survey was pre-tested among nine throm-
bosis physicians at the Ottawa hospital, prior to being dis-
tributed. The evaluation of the current clinical practice
was conducted using a multiple choice option format. In-
formation regarding the type of heparin used for initial
treatment and dosing; the type of heparin used for long-
term-treatment and dosing; and finally the use of anti-Xa
levels to guide therapy during the acute and long term
treatment period was collected. Baseline characteristics of
the respondents including years of practice, specialty, and
knowledge about research methodology, was also cap-
tured. Finally, to ensure that the survey was answered by
physicians with ample experience in the management of
pregnancy associated VTE, a screening question was
inserted at the beginning of the survey trying to iden-
tify physicians who have treated more than two PAVTE
during the last year. This number was reached by con-
sensus among two thrombosis experts (MR and MC).
The survey results are reported using descriptive sta-
tistics (percentages and 95% CI). Stratified analysis was
conducted by years of practice, specialty, and knowledge
about research methods accordingly for each question.
Data was collected using Microsoft excel, and the ana-






% (95% CI) % (95% CI) % (9
Acute treatment DVT 62.3 (50–73) 36.2 (25–48)
PE 62.3 (50–73) 29 (19–40) 5.8
Long-term
treatment
DVT 36.2 (25–48) 34.8 (24–46)





% (95% CI) % (95% CI) % (9
Anti-Xa
monitoring
Acute treatment 20. 4 (12–31) 26 (16–37) 7.2







% (95% CI) % (95% CI) % (9
Peri-partum
Management
VTE > 4 weeks 0 0 53.6
VTE <4
and >2 weeks
0 2.9 (0–9.2) 31.9
VTE <2 weeks 21.7 (15–32) 29 (19–40) 10.1
Abbreviations: DVT Deep vein thrombosis, PE Pulmonary embolism, VTE Venous thro
heparin, UFH Unfractioned heparin, OD once daily, BID Twice daily, IV Intravenous, S
*Special populations were defined as extreme body weights >150 kg or < 40 kg orResults
The survey was electronically mailed to 305 participants;
246 from the ISOM and 54 from TIGC. One hundred
and five of 305 (35%) started answering the survey, of
which 5 (4.5%) were disqualified after the initial screen-
ing question, and 69/305 (22.6%) completed the entire
survey. The final sample consisted of 27/69 hematolo-
gists (39.1%), 30/69 internists (43.5%), 8/69 obstetricians
(11.6%), and 4/69 from other specialties (5.7%). Eight
out of sixty nine had practiced medicine less than 5 years,
11/69 (15.9%) between 5 to 10 years, 14/69 (20.3%) be-
tween 10 to 15 and 36/69 (52.1%) more than 15 years.
For the acute treatment of pregnant patients with deep
vein thrombosis (DVT), 42/69 (60.8%) preferred LMWH
given twice a day whereas 25/69 (36.2%) prescribed it
once daily. These results were similar for patients with
pulmonary embolism (PE), although 6% of the respon-
dents favored UFH for the initial treatment period. More
than 70% of the respondents favored treatment with full
doses of LMWH given once a day or twice a day for
long-term treatment (≥1 month after initiation of antic-
oagulation). An intermediate dose (once a day) was used
by a minority physicians for long term treatment [16/69
(23.2%) for patients diagnosed with DVT and 15/69
(21.7%) for patients diagnosed with PE]. Thirty two phy-
sicians out of 69 (46.3%) reported using anti-Xa moni-
toring during the first 30 days in all patients and 16/69ement and anti-Xa monitoring used by respondents
H IV UFH SC BID LMWH intermediate
dose OD
Other
5% CI) % (95% CI) % (95% CI) % (95% CI)
0 1.4 (0–7) NA 0.14 (0–7)
(2–13) 1.4 (0–7) NA 1.4 (0–7)
NA 0 23.2 (14–34) 5.8 (2–13)
NA 0 21.7 (13–32) 4.4 (1–11)
in special
lations*
Once a month in
special populations*
Never Other
5% CI) % (95% CI) % (95% CI) % (95%CI)
(3–15) 15.9 (9–26) 20.4 (12–31) 10.1 (4–19)
(0–9.2) 30.4 (20–42) 34.8 (24–46) 13.1 (24–46)
H BID UFH SC BID UFH IV Other
5% CI) % (95% CI) % (95% CI) %
(41–65) 18.8 (11–29) 5.8 (2–13) 21.7 (0–9.2)
(21–43) 10.1 (4–19) 39.1 11.7 (5–20)
(4–19) 2.9 (0–9.2) 13.1 (6–22) 20.4 (12–31)
mboembolism, IVC Inferior vena cava filter, LMWH Low molecular weight
C subcutaneous.
creatinine clearance close to 30 ml/min.
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body weight (>150 kg or < 40 kg) or kidney disease (cre-
atinine clearance close to 30 ml/min)] (Table 1). During
long-term treatment, 47/69 (64.8%) answered that they
never used anti-Xa levels or used it only in special popu-
lations, while 13/69 (18.8%) did so on a weekly or monthly
basis in all patients. The use of anti-Xa monitoring varied
according to the strategy used for long-term treatment.
Among those using intermediate doses, 18% used some
form of anti-Xa monitoring for all patients. Among those
using full doses once a day 21% used some form of anti-
Xa monitoring for all patients; whereas 45% of those using
twice a day full doses used monitoring used some form of
anti-Xa monitoring for all patients.
Management during the peri-partum period varied
widely according to the time of the diagnosis of PAVTE.
In those who had a diagnosis more than 4 weeks before
the delivery, 37/69 preferred the use of LMWH twice
daily (53.6%), whereas for those diagnosed within 2 to
4 weeks before delivery 27/69 (39.1%) physicians favored
the use of IV UFH. For those diagnosed within two weeks
of delivery an IVC filter in combination with LMWH or
IV UFH in more was favored by 37/69 (53.2%) of the
respondents.
No association was identified between physician spe-
cialty (p-value >0.05) and years of practice (p-value >0.05)
with respect to dosing and the use of anti-Xa monitoring.
Discussion
Our survey suggests that LMWH is the preferred drug
for the management of PAVTE but that there is wide
variation in dosing strategies and the use of anti-Xa
monitoring. A wide variation in strategies used for the
initial acute and long term treatment period was found
for dosing (once a day vs. twice a day) and for the use of
Anti-Xa monitoring corresponding to the different rec-
ommendations for anti-Xa monitoring and dosing by
available guidelines guidelines [5,6] at the time that the
survey was conducted. The most current recommenda-
tions by the American College of Chest Physicians
(ACCP) Guidelines [1] do not support twice daily dosing
or anti-Xa monitoring. One relevant finding was that
nearly a quarter of the physicians used a reduced dose
strategy for long-term treatment of both DVT and PE.
This strategy has been recommended by experts [7] and
acknowledge in the last two versions of the ACCP
Guidelines [1,5] as an alternative to full dose anticoagu-
lation in selected patients, but has never been correctly
tested in this popualtion [8]. Our findings are consistent
with the systematic review by Romualdi et al. [9] wide
variation in the regimens used for the treatment of
PAVTE. Although our findings regarding dosing strat-
egies for long term treatment are similar to prior studies
conducted by Voke et al. [3] and Knight et al. [10], ourstudy showed decrease in the use of anti-Xa level moni-
toring. The study by Voke et al. reported that 76% of
physicians used anti-Xa level during treatment, but did
not specifically report the responses for long term treat-
ment period. Finally most of the physicians answering
the survey were not obstetricians, a phenomenon also
observed in a study by Coppeltone et al. [11]. This find-
ing may represent the current trend wherein the care of
patients who develop conditions such as PAVTE during
pregnancy is transferred to internal medicine specialists.
Our survey has limitations. Our response rate was low,
despite multiple efforts to increase the response rate.
Since the initial response rate was low (<15%) following
the 2 electronic reminders, two additional measures
were taken to increase the response rate: 1-the survey
was endorsed by three highly respected experts; and
2-compensation in the form of a voluntary raffle. One
factor that could explain our rates is that the number
of studies that use e-mail to collect data has been in-
creasing over the last years while the average re-
sponse rate to the surveys appears to be decreasing
[12,13]. Finally, we cannot exclude that our results re-
flect the practice of those with an interest in the manage-
ment of PAVTE and leading to a bias interpretation of
current practices.
In conclusion, our survey shows wide variation in
practice regarding LMWH dosing and anti-Xa monitor-
ing in pregnancy associated VTE and calls for trials
comparing different long term strategies using LMWH
in patients with PAVTE.
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